ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
信息服務
5.19
+0.1200
2.37%
成交量：
15.99萬
成交額：
82.86萬
市值：
2.51億
市盈率：
21.64
高：
5.21
開：
5.12
低：
5.09
收：
5.07
52周最高：
6.45
52周最低：
3.74
股本：
4,841.35萬
流通股本：
3,555.23萬
量比：
0.94
換手率：
0.45%
股息：
0.18
股息率：
3.47%
每股收益(TTM):
0.2399
每股收益(LYR):
0.1900
淨資產收益率：
12.30%
總資產收益率：
6.36%
市淨率：
2.62
市盈率(LYR):
27.32
資料載入中...
總覽
公司
新聞
公告
ST萬邦(002082.SZ)：石杉鹼甲控釋片II/III期臨床試驗完成200例受試者入組
智通财经
·
06/05
依託成熟毒素平台 百利天恒BL-M05D1胃癌III期試驗完成首例入組
财中社
·
06/04
復宏漢霖H藥III期臨床研究數據登頂《柳葉刀》與ASCO 開創胃癌圍術期「去化療」新範式
中国网财经
·
06/02
Karyopharm將邀專家解讀骨髓纖維化III期SENTRY試驗結果
环球市场播报
·
06/01
港股異動 | 開拓藥業-B(09939)升逾10% KX-826 III期數據亮相WCHR 2026
智通财经
·
06/01
康寧傑瑞製藥-B(09966)：安尼妥單抗(KN026)新輔助治療BC的III期臨床研究結果於2026 ASCO年會以LBA口頭報告形式呈列
智通财经
·
06/01
石藥集團(01093)：KN026聯合HB1801新輔助治療HER2陽性乳腺癌的III期臨床研究結果於2026年ASCO年會以LBA口頭報告形式呈列
智通财经
·
06/01
中國生物製藥(01177)：貝莫蘇拜單抗聯合安羅替尼一線治療非鱗狀非小細胞肺癌於2026 ASCO公布III期臨床數據
智通财经
·
06/01
開拓藥業-B(09939)：KX-826於WCHR 2026公布治療雄激素脱髮的III期臨床試驗及聯合治療研究數據，並獲選傑出海報
智通财经
·
06/01
BMS多發性骨髓瘤III期數據亮眼 C4 Therapeutics受提振大漲
环球市场播报
·
05/30
港股異動 | 中國生物製藥(01177)升逾4% 與GSK合作的Bepirovirsen將於EASL 2026公布兩項III期臨床數據
智通财经
·
05/29
港股異動 | 德琪醫藥-B(06996)升逾5% ATG-022 ADC治療相關胃腺癌關鍵性III期CLINCH-3研究獲臨床批件
智通财经
·
05/29
中國生物製藥(01177)：BEPIROVIRSEN於EASL 2026公布兩項III期臨床數據
智通财经
·
05/29
德琪醫藥-B(06996)：ATG-022用於治療CLDN18.2+晚期胃或胃食管結合部(GEJ)腺癌的關鍵性III期CLINCH-3研究獲中國臨床批件
智通财经
·
05/28
核心III期數據進入倒計時，Vistagen將出席Jefferies全球醫療保健年會
环球市场播报
·
05/27
上海醫藥：截至2026年第一季度B001項目用於治療視神經脊髓炎（NMOSD）的III期臨床試驗主研究（RCP）已完成揭盲
证券日报网
·
05/27
新聞稿：G-III Apparel Group宣佈季度股息
投资观察
·
05/27
恒瑞III期臨床試驗成功，GLP-1百億美元賽道再添玩家
21世纪经济报道
·
05/27
思路迪醫藥股份(01244)：恩維達®聯合GEMOX一線治療晚期膽道癌III期研究結果在2026年ASCO年會正式發布
智通财经
·
05/27
MediWound第一財季業績前瞻：EscharEx III期數據成關注焦點
环球市场播报
·
05/27
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/III/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"III","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服務","latestPrice":5.19,"timestamp":1789156800000,"preClose":5.07,"halted":0,"volume":159870,"delay":0,"changeRate":0.023668639053254458,"floatShares":35552300,"shares":48413462,"eps":0.239856,"marketStatus":"盤前交易","change":0.12,"latestTime":"09-14 04:46:35 EDT","open":5.12,"high":5.2055,"low":5.09,"amount":828609.6472049999,"amplitude":0.022781,"askPrice":5.65,"askSize":407,"bidPrice":3.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.239856,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":5.19,"dividendRate":0.034682,"postHourTrading":{"tag":"盘后","latestPrice":5.1942,"preClose":5.19,"latestTime":"18:01 EDT","volume":6848,"amount":35538.93,"timestamp":1789164063186,"change":0.0042,"changeRate":0.000809,"amplitude":0.000809},"volumeRatio":0.9375505815927984,"impliedVol":1.2381,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","floatShares":35552300,"roa":"6.36%","roe":"12.30%","lyrEps":0.19,"volumeRatio":0.9375505815927984,"shares":48413462,"dividePrice":0.18,"high":5.2055,"amplitude":0.022781,"preClose":5.07,"low":5.09,"week52Low":3.74,"pbRate":"2.62","psRate":"1.00","week52High":6.4495,"institutionHeld":0.6836,"latestPrice":5.19,"committee":-0.605523,"eps":0.239856,"divideRate":0.034682,"volume":159870,"delay":0,"ttmEps":0.239856,"open":5.12,"prevYearClose":5.78,"prevWeekClose":5.19,"prevMonthClose":5.12,"prevQuarterClose":4.11,"fiveDayClose":5.13,"twentyDayClose":5.17,"sixtyDayClose":4.12,"dividendPayoutRate":0.9280598907982862,"dividendFrequency":"Q","dividendGrowthYears":4,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.03333720106347336},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/III\",params:#limit:5,,,undefined,":[{"date":"2026-09-04","symbol":"III","amount":0.045,"announcedDate":"2026-08-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-04","defaultRemindTime":1788528600000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-04","currency":"USD","dateTimestamp":1788494400000,"payDate":"2026-09-25"},{"market":"US","date":"2026-08-05","symbol":"III","fiscalQuarterEnding":"2026/06","expectedEps":0.06,"name":null,"time":"盤後","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":0.07},{"date":"2026-06-05","symbol":"III","amount":0.045,"announcedDate":"2026-05-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-05","defaultRemindTime":1780666200000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-05","currency":"USD","dateTimestamp":1780632000000,"payDate":"2026-06-26"},{"market":"US","date":"2026-05-07","symbol":"III","fiscalQuarterEnding":"2026/03","expectedEps":0.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":0.06},{"date":"2026-03-20","symbol":"III","amount":0.045,"announcedDate":"2026-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"III\",market:\"US\",,,undefined,":[{"executeDate":"2021-06-03","recordDate":"2021-06-04","paymentDate":"2021-06-18","value":0.03,"currency":"USD"},{"executeDate":"2021-09-03","recordDate":"2021-09-07","paymentDate":"2021-09-24","value":0.03,"currency":"USD"},{"executeDate":"2021-12-02","recordDate":"2021-12-03","paymentDate":"2021-12-17","value":0.03,"currency":"USD"},{"executeDate":"2022-03-18","recordDate":"2022-03-21","paymentDate":"2022-04-06","value":0.03,"currency":"USD"},{"executeDate":"2022-06-02","recordDate":"2022-06-03","paymentDate":"2022-06-17","value":0.04,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"III\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1679457600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/III\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"III","date":"2026-09-11","current":21.637983,"percent":0.61645,"low":-221.876594,"twenty":12.58915,"median":18.223516,"eighty":29.237367,"high":68.328883,"avg":0.809935,"sd":58.867544,"marketCap":245456252},"quantilePoints":[{"date":"2021-09-17","current":33.210859,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":366382200},{"date":"2021-09-24","current":32.859422,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":362505139},{"date":"2021-10-01","current":31.936898,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":352327856},{"date":"2021-10-08","current":33.386578,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-15","current":31.849038,"twenty":29.673426,"median":36.811685,"eighty":53.929654,"marketCap":351358591},{"date":"2021-10-22","current":33.386578,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-29","current":35.802712,"twenty":29.76934,"median":36.811685,"eighty":53.929654,"marketCap":394975520},{"date":"2021-11-05","current":32.443868,"twenty":29.838435,"median":36.811685,"eighty":53.929654,"marketCap":434715388},{"date":"2021-11-12","current":34.955794,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":468372678},{"date":"2021-11-19","current":34.77297,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":465923030},{"date":"2021-11-26","current":30.348649,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":406641551},{"date":"2021-12-03","current":28.886064,"twenty":29.82833,"median":36.811685,"eighty":53.929654,"marketCap":387044368},{"date":"2021-12-10","current":29.507663,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":395373171},{"date":"2021-12-17","current":26.984703,"twenty":29.661234,"median":36.811685,"eighty":53.929654,"marketCap":361568030},{"date":"2021-12-23","current":28.081642,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":376265917},{"date":"2021-12-31","current":27.862254,"twenty":29.504246,"median":36.811685,"eighty":53.929654,"marketCap":373326339},{"date":"2022-01-07","current":26.399668,"twenty":29.437039,"median":36.760945,"eighty":53.927618,"marketCap":353729156},{"date":"2022-01-14","current":25.302729,"twenty":29.255815,"median":36.760945,"eighty":53.927618,"marketCap":339031269},{"date":"2022-01-21","current":23.145416,"twenty":29.125104,"median":36.760945,"eighty":53.927618,"marketCap":310125424},{"date":"2022-01-28","current":22.670075,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":303756339},{"date":"2022-02-04","current":24.863954,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":333152114},{"date":"2022-02-11","current":25.887763,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":346870142},{"date":"2022-02-18","current":27.130961,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":363527748},{"date":"2022-02-25","current":26.107151,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":349809720},{"date":"2022-03-04","current":27.423478,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":367447185},{"date":"2022-03-11","current":22.999463,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":357158663},{"date":"2022-03-18","current":22.63323,"twenty":28.930434,"median":36.760945,"eighty":53.927618,"marketCap":351471428},{"date":"2022-03-25","current":21.138876,"twenty":28.720555,"median":36.760945,"eighty":53.927618,"marketCap":328265612},{"date":"2022-04-01","current":21.387935,"twenty":28.563876,"median":36.760945,"eighty":53.927618,"marketCap":332133248},{"date":"2022-04-08","current":20.640759,"twenty":28.47654,"median":36.760945,"eighty":53.927618,"marketCap":320530340},{"date":"2022-04-14","current":20.79642,"twenty":28.362763,"median":36.760945,"eighty":53.927618,"marketCap":322947612},{"date":"2022-04-22","current":19.769052,"twenty":28.214177,"median":36.760945,"eighty":53.927618,"marketCap":306993613},{"date":"2022-04-29","current":19.519993,"twenty":28.004454,"median":36.760945,"eighty":53.927618,"marketCap":303125977},{"date":"2022-05-06","current":18.430361,"twenty":27.931066,"median":36.760945,"eighty":53.927618,"marketCap":286205069},{"date":"2022-05-13","current":17.907825,"twenty":27.846885,"median":36.556933,"eighty":53.927618,"marketCap":305059795},{"date":"2022-05-20","current":17.625134,"twenty":27.555111,"median":36.381032,"eighty":53.927618,"marketCap":300244158},{"date":"2022-05-27","current":18.472496,"twenty":27.379781,"median":36.238493,"eighty":53.927618,"marketCap":314678973},{"date":"2022-06-03","current":18.274778,"twenty":27.167526,"median":36.092994,"eighty":53.927618,"marketCap":311310849},{"date":"2022-06-10","current":16.269354,"twenty":26.614253,"median":35.829538,"eighty":53.927618,"marketCap":277148453},{"date":"2022-06-17","current":16.551809,"twenty":26.372596,"median":35.640231,"eighty":53.822908,"marketCap":281960058},{"date":"2022-06-24","current":17.879343,"twenty":26.107151,"median":35.537925,"eighty":53.79462,"marketCap":304574602},{"date":"2022-07-01","current":19.093895,"twenty":25.975518,"median":35.458953,"eighty":53.271145,"marketCap":325264504},{"date":"2022-07-08","current":19.856521,"twenty":25.412423,"median":35.283172,"eighty":53.041064,"marketCap":338255838},{"date":"2022-07-15","current":19.291613,"twenty":24.849328,"median":35.178625,"eighty":52.906055,"marketCap":328632628},{"date":"2022-07-22","current":20.138975,"twenty":24.08147,"median":35.060591,"eighty":52.665026,"marketCap":343067443},{"date":"2022-07-29","current":21.071074,"twenty":23.209281,"median":34.955794,"eighty":52.523833,"marketCap":358945740},{"date":"2022-08-05","current":21.635982,"twenty":22.947966,"median":34.77297,"eighty":52.322009,"marketCap":368568950},{"date":"2022-08-12","current":16.409925,"twenty":22.628286,"median":34.72983,"eighty":52.322009,"marketCap":293507911},{"date":"2022-08-19","current":16.552576,"twenty":22.371718,"median":34.475053,"eighty":52.322009,"marketCap":296059374},{"date":"2022-08-26","current":16.15211,"twenty":21.544722,"median":34.282985,"eighty":52.322009,"marketCap":288896647},{"date":"2022-09-02","current":14.950714,"twenty":21.183009,"median":34.23369,"eighty":52.322009,"marketCap":267408467},{"date":"2022-09-09","current":14.817225,"twenty":21.074397,"median":34.193624,"eighty":52.322009,"marketCap":265020891},{"date":"2022-09-16","current":14.123085,"twenty":20.842582,"median":34.06831,"eighty":52.322009,"marketCap":252605498},{"date":"2022-09-23","current":12.948386,"twenty":20.628306,"median":33.98562,"eighty":52.322009,"marketCap":231594833},{"date":"2022-09-30","current":12.708107,"twenty":20.189817,"median":33.90293,"eighty":52.322009,"marketCap":227297197},{"date":"2022-10-07","current":12.761502,"twenty":19.975152,"median":33.869805,"eighty":52.322009,"marketCap":228252227},{"date":"2022-10-14","current":12.814898,"twenty":19.650749,"median":33.737549,"eighty":52.322009,"marketCap":229207257},{"date":"2022-10-21","current":13.268758,"twenty":19.370558,"median":33.630766,"eighty":52.322009,"marketCap":237325014},{"date":"2022-10-28","current":14.790528,"twenty":19.172983,"median":33.57217,"eighty":52.322009,"marketCap":264543376},{"date":"2022-11-04","current":11.924698,"twenty":18.940931,"median":33.57217,"eighty":52.322009,"marketCap":226819682},{"date":"2022-11-11","current":14.156908,"twenty":18.67839,"median":33.490051,"eighty":52.100253,"marketCap":269278547},{"date":"2022-11-18","current":14.055967,"twenty":18.383013,"median":33.406789,"eighty":51.591958,"marketCap":267358557},{"date":"2022-11-25","current":13.52603,"twenty":17.941577,"median":33.349337,"eighty":51.184669,"marketCap":257278611},{"date":"2022-12-02","current":13.223208,"twenty":17.811433,"median":33.272057,"eighty":50.857754,"marketCap":251518642},{"date":"2022-12-09","current":12.59233,"twenty":17.329516,"median":33.261363,"eighty":50.482919,"marketCap":239518707},{"date":"2022-12-16","current":11.406279,"twenty":16.879455,"median":33.138265,"eighty":50.207132,"marketCap":216958829},{"date":"2022-12-23","current":11.507219,"twenty":16.612253,"median":33.07907,"eighty":49.781169,"marketCap":218878818},{"date":"2022-12-30","current":11.60816,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":220798808},{"date":"2023-01-06","current":12.264273,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":233278741},{"date":"2023-01-13","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-01-20","current":12.970857,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246718668},{"date":"2023-01-27","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-02-03","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-10","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-17","current":13.677441,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":260158596},{"date":"2023-02-24","current":12.945622,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246238671},{"date":"2023-03-03","current":13.500795,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":256798614},{"date":"2023-03-10","current":12.166618,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239998705},{"date":"2023-03-17","current":11.411218,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":225097683},{"date":"2023-03-24","current":12.147425,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239620114},{"date":"2023-03-31","current":12.490989,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":246397249},{"date":"2023-04-06","current":12.294667,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":242524601},{"date":"2023-04-14","current":12.687311,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":250269897},{"date":"2023-04-21","current":12.270127,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":242040520},{"date":"2023-04-28","current":12.196506,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":240588276},{"date":"2023-05-05","current":12.245586,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":241556438},{"date":"2023-05-12","current":13.473902,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":246397249},{"date":"2023-05-19","current":14.20765,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":259815303},{"date":"2023-05-26","current":13.413927,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":245300481},{"date":"2023-06-02","current":13.387469,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":244816654},{"date":"2023-06-09","current":13.943076,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":254977029},{"date":"2023-06-16","current":14.075363,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":257396166},{"date":"2023-06-23","current":15.080746,"twenty":16.529212,"median":33.076029,"eighty":49.624683,"marketCap":275781606},{"date":"2023-06-30","current":14.154735,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":258847648},{"date":"2023-07-07","current":13.810789,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":252557892},{"date":"2023-07-14","current":14.260565,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":260782957},{"date":"2023-07-21","current":14.048906,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":256912338},{"date":"2023-07-28","current":13.387469,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":244816654},{"date":"2023-08-04","current":16.278939,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":254977029},{"date":"2023-08-11","current":16.275803,"twenty":16.382336,"median":32.997393,"eighty":49.558778,"marketCap":254927904},{"date":"2023-08-18","current":15.376759,"twenty":16.278939,"median":32.930248,"eighty":49.391703,"marketCap":240846172},{"date":"2023-08-25","current":15.40776,"twenty":16.232204,"median":32.835614,"eighty":49.042233,"marketCap":241331749},{"date":"2023-09-01","current":16.120795,"twenty":16.15211,"median":32.803437,"eighty":48.925743,"marketCap":252500019},{"date":"2023-09-08","current":15.035742,"twenty":16.031821,"median":32.75433,"eighty":48.809254,"marketCap":235504825},{"date":"2023-09-15","current":14.446713,"twenty":15.779779,"median":32.64723,"eighty":48.576274,"marketCap":226278863},{"date":"2023-09-22","current":13.733678,"twenty":15.562768,"median":32.609831,"eighty":48.459784,"marketCap":215110593},{"date":"2023-09-29","current":13.423662,"twenty":15.404575,"median":32.491023,"eighty":48.459784,"marketCap":210254823},{"date":"2023-10-06","current":13.950688,"twenty":15.345757,"median":32.431996,"eighty":48.459784,"marketCap":218509632},{"date":"2023-10-13","current":13.361659,"twenty":15.080746,"median":32.334816,"eighty":48.343294,"marketCap":209283669},{"date":"2023-10-20","current":13.051644,"twenty":14.911736,"median":32.178609,"eighty":48.324535,"marketCap":204427900},{"date":"2023-10-27","current":12.77263,"twenty":14.827387,"median":32.156546,"eighty":48.226804,"marketCap":200057707},{"date":"2023-11-03","current":15.032891,"twenty":14.614323,"median":32.100506,"eighty":48.180208,"marketCap":200057707},{"date":"2023-11-10","current":15.314305,"twenty":14.614323,"median":32.044484,"eighty":48.063719,"marketCap":203802770},{"date":"2023-11-17","current":15.975354,"twenty":14.614323,"median":32.022403,"eighty":47.932458,"marketCap":212600012},{"date":"2023-11-24","current":16.048804,"twenty":14.614323,"median":31.943078,"eighty":47.714249,"marketCap":213577483},{"date":"2023-12-01","current":15.27758,"twenty":14.614323,"median":31.841671,"eighty":47.187487,"marketCap":203314034},{"date":"2023-12-08","current":16.673128,"twenty":14.619662,"median":31.750721,"eighty":46.490677,"marketCap":221885989},{"date":"2023-12-15","current":16.673128,"twenty":14.619662,"median":31.53949,"eighty":46.22662,"marketCap":221885989},{"date":"2023-12-22","current":17.407627,"twenty":14.619662,"median":31.467912,"eighty":45.230776,"marketCap":231660702},{"date":"2023-12-29","current":17.554527,"twenty":14.614323,"median":31.234022,"eighty":45.040598,"marketCap":233615645},{"date":"2024-01-05","current":16.673128,"twenty":14.608983,"median":31.080268,"eighty":44.740412,"marketCap":221885989},{"date":"2024-01-12","current":16.452778,"twenty":14.608983,"median":30.97496,"eighty":44.593596,"marketCap":218953575},{"date":"2024-01-19","current":16.269154,"twenty":14.603644,"median":30.818124,"eighty":44.593596,"marketCap":216509897},{"date":"2024-01-26","current":17.554527,"twenty":14.608983,"median":30.62605,"eighty":44.463847,"marketCap":233615645},{"date":"2024-02-02","current":16.820028,"twenty":14.608983,"median":30.523385,"eighty":44.220503,"marketCap":223840932},{"date":"2024-02-09","current":16.122254,"twenty":14.608983,"median":30.418362,"eighty":43.923358,"marketCap":214554954},{"date":"2024-02-16","current":16.305879,"twenty":14.608983,"median":30.260593,"eighty":43.769861,"marketCap":216998633},{"date":"2024-02-23","current":15.608105,"twenty":14.608983,"median":30.141793,"eighty":42.75327,"marketCap":207712655},{"date":"2024-03-01","current":15.901904,"twenty":14.614323,"median":30.092043,"eighty":42.030433,"marketCap":211622540},{"date":"2024-03-08","current":34.784891,"twenty":14.614323,"median":29.930691,"eighty":41.395649,"marketCap":214066219},{"date":"2024-03-15","current":30.710223,"twenty":14.614323,"median":29.930691,"eighty":41.308941,"marketCap":188990710},{"date":"2024-03-22","current":32.281078,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":198657754},{"date":"2024-03-28","current":31.652736,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":194790936},{"date":"2024-04-05","current":31.966907,"twenty":14.608983,"median":30.092453,"eighty":41.339259,"marketCap":196724345},{"date":"2024-04-12","current":30.238966,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":186090597},{"date":"2024-04-19","current":28.589568,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":175940200},{"date":"2024-04-26","current":27.411426,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":168689917},{"date":"2024-05-03","current":26.39037,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":162406339},{"date":"2024-05-10","current":25.919114,"twenty":14.614323,"median":30.117759,"eighty":41.308941,"marketCap":159506226},{"date":"2024-05-17","current":-211.151442,"twenty":14.503289,"median":29.916131,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-24","current":-211.151442,"twenty":14.319403,"median":29.768426,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-31","current":-216.514018,"twenty":14.260565,"median":29.603046,"eighty":41.308941,"marketCap":157189177},{"date":"2024-06-07","current":-209.810798,"twenty":14.204967,"median":29.476834,"eighty":41.308941,"marketCap":152322639},{"date":"2024-06-14","current":-212.492085,"twenty":14.156908,"median":29.278446,"eighty":41.339259,"marketCap":154269254},{"date":"2024-06-21","current":-203.777899,"twenty":14.123085,"median":28.941526,"eighty":41.369578,"marketCap":147942755},{"date":"2024-06-28","current":-205.788865,"twenty":14.101821,"median":28.815898,"eighty":41.369578,"marketCap":149402716},{"date":"2024-07-05","current":-205.118543,"twenty":14.061456,"median":28.592041,"eighty":41.369578,"marketCap":148916062},{"date":"2024-07-12","current":-210.48112,"twenty":13.995991,"median":28.46557,"eighty":41.369578,"marketCap":152809293},{"date":"2024-07-15","current":-211.151442,"twenty":13.995991,"median":28.446337,"eighty":41.369578,"marketCap":153295947},{"date":"2024-08-02","current":-221.876594,"twenty":13.965764,"median":28.594514,"eighty":41.395649,"marketCap":161082407},{"date":"2024-08-09","current":-155.153276,"twenty":13.890161,"median":28.447288,"eighty":41.369578,"marketCap":158411495},{"date":"2024-08-16","current":-157.547617,"twenty":13.879322,"median":28.196854,"eighty":41.040322,"marketCap":160856117},{"date":"2024-08-23","current":-158.026486,"twenty":13.823503,"median":28.008512,"eighty":39.690077,"marketCap":161345042},{"date":"2024-08-30","current":-166.167244,"twenty":13.795681,"median":27.935383,"eighty":38.544,"marketCap":169656756},{"date":"2024-09-06","current":-154.195541,"twenty":13.753035,"median":27.569737,"eighty":38.347232,"marketCap":157433647},{"date":"2024-09-13","current":-151.322331,"twenty":13.704502,"median":27.313784,"eighty":38.122137,"marketCap":154500100},{"date":"2024-09-20","current":-156.111013,"twenty":13.672394,"median":27.130961,"eighty":37.980944,"marketCap":159389344},{"date":"2024-09-27","current":-154.195541,"twenty":13.62697,"median":26.595041,"eighty":37.894382,"marketCap":157433647},{"date":"2024-10-04","current":-155.153276,"twenty":13.599214,"median":26.468913,"eighty":37.779744,"marketCap":158411495},{"date":"2024-10-11","current":-150.364595,"twenty":13.553316,"median":26.233285,"eighty":37.589923,"marketCap":153522252},{"date":"2024-10-18","current":-152.280068,"twenty":13.524775,"median":26.107151,"eighty":37.433759,"marketCap":155477949},{"date":"2024-10-25","current":-147.012518,"twenty":13.48942,"median":25.919114,"eighty":37.27024,"marketCap":150099781},{"date":"2024-10-31","current":-150.364595,"twenty":13.450324,"median":25.485552,"eighty":37.015362,"marketCap":153522252},{"date":"2024-11-08","current":-52.964156,"twenty":13.423662,"median":24.845672,"eighty":36.750798,"marketCap":162811815},{"date":"2024-11-15","current":-53.318651,"twenty":13.387469,"median":24.004684,"eighty":36.556933,"marketCap":163901532},{"date":"2024-11-22","current":-53.238832,"twenty":13.341574,"median":23.198637,"eighty":36.327656,"marketCap":163656170},{"date":"2024-11-29","current":-58.905934,"twenty":13.314055,"median":22.981027,"eighty":36.238493,"marketCap":181076842},{"date":"2024-12-06","current":-58.267387,"twenty":13.27171,"median":22.651653,"eighty":35.999189,"marketCap":179113949},{"date":"2024-12-13","current":-58.427024,"twenty":13.239501,"median":22.455197,"eighty":35.783905,"marketCap":179604672},{"date":"2024-12-20","current":-55.074654,"twenty":13.19425,"median":21.621859,"eighty":35.607032,"marketCap":169299486},{"date":"2024-12-27","current":-53.957197,"twenty":13.130069,"median":21.342486,"eighty":35.505726,"marketCap":165864424},{"date":"2025-01-03","current":-51.88192,"twenty":13.070245,"median":21.138876,"eighty":35.459393,"marketCap":159485023},{"date":"2025-01-10","current":-49.96628,"twenty":13.021327,"median":20.901601,"eighty":35.211692,"marketCap":153596345},{"date":"2025-01-17","current":-51.88192,"twenty":12.972548,"median":20.664813,"eighty":35.117714,"marketCap":159485023},{"date":"2025-01-24","current":-51.562647,"twenty":12.952487,"median":20.578494,"eighty":35.032487,"marketCap":158503577},{"date":"2025-01-31","current":-49.168097,"twenty":12.915203,"median":20.138975,"eighty":34.93156,"marketCap":151142730},{"date":"2025-02-07","current":-51.083737,"twenty":12.802486,"median":19.831317,"eighty":34.780123,"marketCap":157031408},{"date":"2025-02-14","current":-51.40301,"twenty":12.725025,"median":19.519993,"eighty":34.72983,"marketCap":158012854},{"date":"2025-02-21","current":-49.48737,"twenty":12.667751,"median":19.333199,"eighty":34.575342,"marketCap":152124176},{"date":"2025-02-28","current":-49.00846,"twenty":12.601316,"median":19.122141,"eighty":34.324158,"marketCap":150652007},{"date":"2025-03-07","current":53.583718,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":152124176},{"date":"2025-03-14","current":56.52218,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":160466470},{"date":"2025-03-21","current":63.229713,"twenty":12.589786,"median":18.928478,"eighty":34.39907,"marketCap":179509154},{"date":"2025-03-28","current":64.079574,"twenty":12.589786,"median":18.928478,"eighty":34.546571,"marketCap":181921911},{"date":"2025-04-04","current":63.569657,"twenty":12.589786,"median":18.928478,"eighty":34.686729,"marketCap":180474257},{"date":"2025-04-11","current":60.17021,"twenty":12.590422,"median":18.990743,"eighty":34.733776,"marketCap":170823227},{"date":"2025-04-17","current":62.889768,"twenty":12.590422,"median":18.990743,"eighty":34.814432,"marketCap":178544051},{"date":"2025-04-25","current":62.379851,"twenty":12.589786,"median":18.928478,"eighty":34.943677,"marketCap":177096396},{"date":"2025-05-02","current":64.589491,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":183369566},{"date":"2025-05-09","current":25.015629,"twenty":12.589786,"median":18.928478,"eighty":35.046539,"marketCap":193020596},{"date":"2025-05-16","current":29.987043,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":231380025},{"date":"2025-05-23","current":29.29984,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":226077566},{"date":"2025-05-30","current":29.237367,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":225595524},{"date":"2025-06-06","current":29.424786,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":227041650},{"date":"2025-06-13","current":29.862097,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":230415942},{"date":"2025-06-20","current":29.612205,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":228487775},{"date":"2025-06-27","current":28.862529,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":222703274},{"date":"2025-07-03","current":31.923706,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":246323318},{"date":"2025-07-11","current":31.486395,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":242949026},{"date":"2025-07-18","current":29.237367,"twenty":12.58915,"median":18.866214,"eighty":34.89521,"marketCap":225595524},{"date":"2025-07-25","current":28.425218,"twenty":12.58915,"median":18.866214,"eighty":34.834126,"marketCap":219328982},{"date":"2025-08-01","current":26.925866,"twenty":12.58915,"median":18.866214,"eighty":34.784891,"marketCap":207759981},{"date":"2025-08-08","current":25.754678,"twenty":12.58915,"median":18.866214,"eighty":34.77297,"marketCap":202457522},{"date":"2025-08-15","current":30.470866,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":239531480},{"date":"2025-08-22","current":29.489913,"twenty":12.58915,"median":18.866214,"eighty":34.221243,"marketCap":231820205},{"date":"2025-08-29","current":31.39051,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":246760801},{"date":"2025-09-05","current":32.432773,"twenty":12.58915,"median":18.85295,"eighty":34.118522,"marketCap":254954031},{"date":"2025-09-12","current":32.126225,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":252544257},{"date":"2025-09-19","current":33.965513,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":267002898},{"date":"2025-09-26","current":35.314324,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":277605901},{"date":"2025-10-03","current":34.639918,"twenty":12.58915,"median":18.866214,"eighty":34.639918,"marketCap":272304399},{"date":"2025-10-10","current":33.842894,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":266038988},{"date":"2025-10-17","current":33.413727,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":262665306},{"date":"2025-10-24","current":34.088132,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":267966807},{"date":"2025-10-31","current":33.536346,"twenty":12.58915,"median":18.866214,"eighty":34.748399,"marketCap":263629215},{"date":"2025-11-07","current":28.380485,"twenty":12.58915,"median":18.866214,"eighty":34.701228,"marketCap":277248962},{"date":"2025-11-14","current":25.733601,"twenty":12.58915,"median":18.866214,"eighty":34.517299,"marketCap":251391546},{"date":"2025-11-21","current":24.557208,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":239899361},{"date":"2025-11-28","current":26.370814,"twenty":12.58915,"median":18.866214,"eighty":34.210751,"marketCap":257616479},{"date":"2025-12-05","current":28.282453,"twenty":12.58915,"median":18.866214,"eighty":33.965513,"marketCap":276291280},{"date":"2025-12-12","current":29.409829,"twenty":12.58915,"median":18.866214,"eighty":33.842894,"marketCap":287304624},{"date":"2025-12-19","current":29.26278,"twenty":12.58915,"median":18.866214,"eighty":33.529773,"marketCap":285868100},{"date":"2025-12-26","current":29.066715,"twenty":12.58915,"median":18.866214,"eighty":33.430508,"marketCap":283952736},{"date":"2026-01-02","current":28.331469,"twenty":12.58915,"median":18.866214,"eighty":33.342648,"marketCap":276770121},{"date":"2026-01-09","current":29.164747,"twenty":12.58915,"median":18.866214,"eighty":33.210859,"marketCap":284910418},{"date":"2026-01-16","current":29.80196,"twenty":12.58915,"median":18.866214,"eighty":33.054432,"marketCap":291135352},{"date":"2026-01-23","current":27.792289,"twenty":12.58915,"median":18.866214,"eighty":32.903351,"marketCap":271502869},{"date":"2026-01-30","current":27.400158,"twenty":12.58915,"median":18.866214,"eighty":32.739321,"marketCap":267672141},{"date":"2026-02-06","current":24.998355,"twenty":12.58915,"median":18.866214,"eighty":32.548436,"marketCap":244208930},{"date":"2026-02-13","current":22.35147,"twenty":12.58915,"median":18.866214,"eighty":32.359621,"marketCap":218351514},{"date":"2026-02-20","current":22.841634,"twenty":12.58915,"median":18.866214,"eighty":32.126225,"marketCap":223139924},{"date":"2026-02-27","current":23.429831,"twenty":12.58915,"median":18.866214,"eighty":32.068687,"marketCap":228886017},{"date":"2026-03-06","current":24.400849,"twenty":12.58915,"median":18.866214,"eighty":31.936898,"marketCap":227928335},{"date":"2026-03-13","current":20.466129,"twenty":12.58915,"median":18.866214,"eighty":31.809821,"marketCap":191174107},{"date":"2026-03-20","current":19.649525,"twenty":12.58915,"median":18.866214,"eighty":31.731279,"marketCap":183546212},{"date":"2026-03-27","current":19.7516,"twenty":12.58915,"median":18.866214,"eighty":31.635749,"marketCap":184499699},{"date":"2026-04-02","current":19.598487,"twenty":12.58915,"median":18.866214,"eighty":31.486395,"marketCap":183069469},{"date":"2026-04-10","current":20.415091,"twenty":12.58915,"median":18.866214,"eighty":31.417108,"marketCap":190697364},{"date":"2026-04-17","current":21.282732,"twenty":12.58915,"median":18.866214,"eighty":31.338565,"marketCap":198802001},{"date":"2026-04-24","current":20.466129,"twenty":12.58915,"median":18.866214,"eighty":31.102233,"marketCap":191174107},{"date":"2026-05-01","current":20.823393,"twenty":12.58915,"median":18.866214,"eighty":30.970444,"marketCap":194511311},{"date":"2026-05-08","current":18.809916,"twenty":12.58915,"median":18.839687,"eighty":30.838724,"marketCap":198802001},{"date":"2026-05-15","current":19.2371,"twenty":12.58915,"median":18.809916,"eighty":30.611773,"marketCap":203316914},{"date":"2026-05-22","current":19.780266,"twenty":12.58915,"median":18.739199,"eighty":30.409557,"marketCap":209057627},{"date":"2026-05-29","current":20.504486,"twenty":12.58915,"median":18.718829,"eighty":30.267569,"marketCap":216711911},{"date":"2026-06-05","current":19.644474,"twenty":12.58915,"median":18.739199,"eighty":30.174462,"marketCap":207622449},{"date":"2026-06-12","current":19.372892,"twenty":12.58915,"median":18.739199,"eighty":30.111989,"marketCap":204752092},{"date":"2026-06-18","current":18.829726,"twenty":12.58915,"median":18.698459,"eighty":29.987245,"marketCap":199011379},{"date":"2026-06-26","current":18.377089,"twenty":12.58915,"median":18.492688,"eighty":29.953208,"marketCap":194227452},{"date":"2026-07-02","current":18.965518,"twenty":12.58915,"median":18.492688,"eighty":29.862097,"marketCap":200446558},{"date":"2026-07-10","current":18.422353,"twenty":12.58915,"median":18.42051,"eighty":29.749013,"marketCap":194705845},{"date":"2026-07-17","current":18.558144,"twenty":12.58915,"median":18.377089,"eighty":29.67784,"marketCap":196141023},{"date":"2026-07-24","current":17.381286,"twenty":12.58915,"median":18.28067,"eighty":29.612205,"marketCap":183702812},{"date":"2026-07-31","current":18.648671,"twenty":12.58915,"median":18.223516,"eighty":29.51755,"marketCap":197097808},{"date":"2026-08-07","current":20.47213,"twenty":12.58915,"median":18.223516,"eighty":29.481004,"marketCap":239196370},{"date":"2026-08-14","current":21.422252,"twenty":12.58915,"median":18.223516,"eighty":29.444258,"marketCap":250297598},{"date":"2026-08-21","current":20.427796,"twenty":12.58915,"median":18.223516,"eighty":29.415812,"marketCap":238678367},{"date":"2026-08-28","current":20.883588,"twenty":12.58915,"median":18.223516,"eighty":29.304623,"marketCap":244003848},{"date":"2026-09-04","current":21.25651,"twenty":12.58915,"median":18.223516,"eighty":29.26278,"marketCap":248361060},{"date":"2026-09-11","current":21.007896,"twenty":12.58915,"median":18.223516,"eighty":29.237367,"marketCap":245456252}],"updateTime":1789359179447},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"III\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2641484110","title":"ST萬邦(002082.SZ)：石杉鹼甲控釋片II/III期臨床試驗完成200例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2641484110","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641484110?lang=zh_tw&edition=fundamental","pubTime":"2026-06-05 19:45","pubTimestamp":1780659900,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST万邦(002082.SZ)发布公告，公司全资子公司万邦德制药集团有限公司的2.2类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病型痴呆的II/III期关键注册临床试验，于近日完成200例受试者入组。公司积极推进受试者入组，将继续与首都医科大学宣武医院等全国50多家研究机构紧密合作，进一步验证药物的安全性、有效性，为产品的最终上市申请提供关键数据支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","III","002082","BK0004","BK0050","BK4134","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640197152","title":"依託成熟毒素平台 百利天恒BL-M05D1胃癌III期試驗完成首例入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640197152?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 19:52","pubTimestamp":1780573920,"startTime":"0","endTime":"0","summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760581427.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4023","91194","688506","BK0239","BK4134","BL","LU1815336091.USD","III","02615","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911801","title":"復宏漢霖H藥III期臨床研究數據登頂《柳葉刀》與ASCO 開創胃癌圍術期「去化療」新範式","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911801","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640911801?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 17:30","pubTimestamp":1780392638,"startTime":"0","endTime":"0","summary":"中国网财经6月2日讯复宏汉霖(2696.HK)今日宣布，公司自主研发的创新型抗PD-1单抗H药汉斯状?(斯鲁利单抗)用于胃癌新辅助/辅助治疗的III期临床研究(ASTRUM-006)数据，在2026年美国临床肿瘤学会(ASCO)年会以口头报告的形式首次正式发布，并同步在线发表于国际顶尖医学期刊《柳叶刀》，斩获国际两大顶级学术平台权威认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606023757635031.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606023757635031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4134","HK0000165453.HKD","HK0000306701.USD","02696","HK0000320223.HKD","HK0000306685.HKD","BK1161","HK0000320264.USD","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968887","title":"Karyopharm將邀專家解讀骨髓纖維化III期SENTRY試驗結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968887","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968887?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 22:44","pubTimestamp":1780325040,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc．今日宣布，将于美国东部时间6月2日下午2：00召开投资者电话会议，详细解读selinexor联合ruxolitinib治疗骨髓纤维化的III期SENTRY试验结果。会议将在Mascarenhas博士于2026年美国临床肿瘤学会年会上口头报告试验结果之后举行。 Karyopharm计划与美国食品药品监督管理局讨论整体数据及潜在补充新药申请事宜。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxmef5076533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640935521","title":"港股異動 | 開拓藥業-B(09939)升逾10% KX-826 III期數據亮相WCHR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640935521","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640935521?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 14:12","pubTimestamp":1780294340,"startTime":"0","endTime":"0","summary":"消息面上，6月1日，开拓药业宣布，自主研发、潜在同类首创的KX-826于2026年5月28日至31日在韩国首尔举行的第14届世界毛发研究大会上公布了两项重要临床研究数据。整体结果显示，KX-826在治疗脱发患者中展现出优异的有效性和安全性。该项临床观察试验由江蕾微教授等主导完成，为未来开展KX-826与米诺地尔联合疗法的III期临床试验提供了充分依据。公司表示目前正在积极推动KX-826的上市许可申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","III","BK4585","BK1515","09939","VXUS","BK1161","BK4134","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981528","title":"康寧傑瑞製藥-B(09966)：安尼妥單抗(KN026)新輔助治療BC的III期臨床研究結果於2026 ASCO年會以LBA口頭報告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981528","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640981528?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 08:18","pubTimestamp":1780273113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团附属公司津曼特生物合作开发的安尼妥单抗联合注射用多西他赛新辅助治疗HER2+ BC的III期临床研究的显著性结果已于2026 ASCO年会以LBA口头报告形式呈列。KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评估安尼妥单抗联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在早期及局部晚期HER2+ BC新辅助治疗中的疗效与安全性，主要终点为由BIRC评估的 tpCR。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4190","III","BK1574","BC","BK1161","BK4134","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640813439","title":"石藥集團(01093)：KN026聯合HB1801新輔助治療HER2陽性乳腺癌的III期臨床研究結果於2026年ASCO年會以LBA口頭報告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640813439","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640813439?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 08:13","pubTimestamp":1780272820,"startTime":"0","endTime":"0","summary":"Neo-Healer是一项随机、对照、开放标签、多中心的III期临床试验，旨在比较安尼妥单抗联合HB1801±卡铂与标准THP±卡铂方案新辅助治疗早期和局部晚期HER2阳性乳腺癌患者中的有效性与安全性。研究结果表明，安尼妥单抗联合HB1801±卡铂方案，相比现有标准双重HER2阻断联合化疗方案显著提升了tpCR率，且整体安全性可控，有望成为HER2阳性早期或局部晚期乳腺癌新辅助治疗的全新标准疗法，为这一患者人群带来更有效的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008369823.USD","LU0067412154.USD","LU2039709279.SGD","LU1226287792.SGD","HK0000165453.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","01093","LU1226288253.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1226288170.HKD","LU1993786604.SGD","LU1152091168.USD","LU0880133367.SGD","III","SG9999004220.SGD","LU1960683339.HKD","LU0501845795.SGD","BK1191","LU0072913022.USD","IE00BZ08YT58.USD","LU1813983027.USD","LU1226287529.USD","LU0326950275.SGD","LU1152091754.HKD","IE00BZ08YR35.GBP","LU1328277881.USD","LU1951186391.HKD","LU0314109678.HKD","BK1515","IE0008368742.USD","LU0315179316.USD","LU1807302812.USD","BK4134","LU1008478684.HKD","IE00BZ08YS42.EUR","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989899","title":"中國生物製藥(01177)：貝莫蘇拜單抗聯合安羅替尼一線治療非鱗狀非小細胞肺癌於2026 ASCO公布III期臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989899","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640989899?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 06:58","pubTimestamp":1780268296,"startTime":"0","endTime":"0","summary":"这是继鳞状非小细胞肺癌之后，贝莫苏拜单抗联合安罗替尼在头对头III期临床研究中再次证实优效于替雷利珠单抗联合标准化疗方案，并成为全球首个在非鳞状非小细胞肺癌一线治疗中，相较于“免疫检查点抑制剂联合化疗”取得阳性结果的III期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","BK1521","BK1515","III","IE00BZ08YR35.GBP","BK1191","BK4134","BK1589","HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640986039","title":"開拓藥業-B(09939)：KX-826於WCHR 2026公布治療雄激素脱髮的III期臨床試驗及聯合治療研究數據，並獲選傑出海報","url":"https://stock-news.laohu8.com/highlight/detail?id=2640986039","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640986039?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 06:41","pubTimestamp":1780267278,"startTime":"0","endTime":"0","summary":"整体结果显示，KX-826 在治疗脱发患者中展现出优异的有效性和安全性。与米诺地尔联合治疗中国成年男性脱发的临床观察试验研究数据。该项临床观察试验由江蕾微教授等主导完成，为未来开展KX-826与米诺地尔联合疗法的III期临床试验提供了充分依据。目前，公司正在积极推动KX-826的上市许可申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4134","09939","III","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639725276","title":"BMS多發性骨髓瘤III期數據亮眼 C4 Therapeutics受提振大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2639725276","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639725276?lang=zh_tw&edition=fundamental","pubTime":"2026-05-30 03:49","pubTimestamp":1780084140,"startTime":"0","endTime":"0","summary":"百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这一积极结果不仅推高了施贵宝的股价，也显著提振了同领域生物科技公司C4 Therapeutics的市场表现。 在施贵宝宣布这一消息后，C4 Therapeutics股价应声大涨，盘中一度触及52周新高，最终收涨逾19%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-30/doc-inhzrera0552232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","BK4539","BMS","CCCC","III","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639644648","title":"港股異動 | 中國生物製藥(01177)升逾4% 與GSK合作的Bepirovirsen將於EASL 2026公布兩項III期臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2639644648","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639644648?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 14:33","pubTimestamp":1780036423,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国生物制药涨超4%，截至发稿，涨3.95%，报5港元，成交额4.28亿港元。消息面上，5月29日，中国生物制药发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的Bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。Bepirovirsen目前正在接受中国、美国、欧洲、日本监管机构的审评审批。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSK.UK","BK4532","IE00BZ08YS42.EUR","BK1589","GSK","BK1191","BK4134","BK4588","VXUS","BK4585","IE00BZ08YT58.USD","GSKH","HK0000165453.HKD","III","BK1521","01177","BK4007","BK1515","LU1829250122.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639648279","title":"港股異動 | 德琪醫藥-B(06996)升逾5% ATG-022 ADC治療相關胃腺癌關鍵性III期CLINCH-3研究獲臨床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639648279?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","III","BK1583","BK4134","ADC","BK4585","BK4231","BK4080","BK1574","BK4588","06996","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639143996","title":"中國生物製藥(01177)：BEPIROVIRSEN於EASL 2026公布兩項III期臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2639143996","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639143996?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 06:23","pubTimestamp":1780007004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团附属公司正大天晴药业集团股份有限公司与葛兰素史克合作的bepirovirsen，已公布其用于治疗慢性乙型肝炎的积极关键数据。HBsAg的下降还与89%的肝癌和62%的全因死亡风险降低有关。GSK预计2027年上半年收到中国国家药品监督管理局的监管决定，目前上市准备工作正在进行中。该疾病每年约造成110万人死亡，并导致约56%的全球肝癌病例。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","III","BK1521","BK1515","BK1589","IE00BZ08YR35.GBP","BK4134","IE00BZ08YT58.USD","BK1191","HK0000165453.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632546","title":"德琪醫藥-B(06996)：ATG-022用於治療CLDN18.2+晚期胃或胃食管結合部(GEJ)腺癌的關鍵性III期CLINCH-3研究獲中國臨床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632546","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638632546?lang=zh_tw&edition=fundamental","pubTime":"2026-05-28 07:27","pubTimestamp":1779924430,"startTime":"0","endTime":"0","summary":"作为一项关键注册研究，CLINCH-3旨在支持ATG-022作为单药疗法治疗CLDN18.2+晚期胃癌或胃食管结合部腺癌的未来上市许可申请。本集团无法保证ATG-022最终将成功开发及上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1191","BK1574","BK1583","06996","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638681039","title":"核心III期數據進入倒計時，Vistagen將出席Jefferies全球醫療保健年會","url":"https://stock-news.laohu8.com/highlight/detail?id=2638681039","media":"环球市场播报","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638681039?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 23:28","pubTimestamp":1779895680,"startTime":"0","endTime":"0","summary":"专注于开发新型鼻内给药神经科学药物的Vistagen宣布，公司将出席于2026年6月2日至4日在纽约举行的Jefferies全球医疗保健年会。会议期间，公司管理层将与机构投资者进行一对一交流，介绍其创新的pherine候选药物管线的最新进展。 Vistagen的先导候选药物fasedienol正处于美国注册导向的III期临床开发阶段，用于社交焦虑症的急性治疗。Vistagen认为，若其中任何一项III期试验成功，连同PALISADE-2的积极结果，可能构成提交新药上市申请所需的有效性实质证据。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzkfve8244142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VHT","XLV","BK4585","BK4581","BK4550","BK4134","III","BK4588","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638832606","title":"上海醫藥：截至2026年第一季度B001項目用於治療視神經脊髓炎（NMOSD）的III期臨床試驗主研究（RCP）已完成揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2638832606","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638832606?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 20:32","pubTimestamp":1779885120,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯，上海医药在接受调研者提问时表示，截至2026年第一季度，B001项目用于治疗视神经脊髓炎(NMOSD)的III期临床试验主研究(RCP)已完成揭盲。研究结果显示，B001较安慰剂可显著降低AQP4-IGG阳性NMOSD的复发风险；并且B001较已获批同类药物具备更好的安全性，输液相关不良反应、感染相关不良反应、免疫球蛋白降低和血液学相关不良反应的发生率均更低。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0209","BK0175","BK1197","BK0012","601607","III","BK4134","BK0020","BK0028","BK0097","BK0183","BK0196","BK0099","BK0184","BK0187","BK0188","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181240785","title":"新聞稿：G-III Apparel Group宣佈季度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1181240785","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181240785?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879647,"startTime":"0","endTime":"0","summary":"纽约，2026年5月27日——G-III Apparel Group, Ltd.今日宣布，其董事会已批准派发每股0.10美元的季度现金股息。此次股息将于2026年7月8日支付给截至2026年6月22日登记在册的股东。G-III Apparel Group, Ltd.是一家全球时尚领域的领导者，在设计、采购、分销和营销方面拥有深厚专长。涉及G-III对未来事件预期的陈述属于联邦证券法所定义的“前瞻性陈述”。G-III不承担更新本新闻稿中信息的义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","GIII","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638509247","title":"恒瑞III期臨床試驗成功，GLP-1百億美元賽道再添玩家","url":"https://stock-news.laohu8.com/highlight/detail?id=2638509247","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638509247?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 18:14","pubTimestamp":1779876840,"startTime":"0","endTime":"0","summary":"5月27日，恒瑞医药与美国KaileraTherapeutics公司共同宣布：其口服小分子GLP-1受体激动剂HRS-7535在中国284名成人2型糖尿病受试者中开展的Ⅲ期临床试验OUTSTAND-1取得积极顶线结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605273751419649.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605273751419649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GLP","BK4590","III","BK4144","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638546521","title":"思路迪醫藥股份(01244)：恩維達®聯合GEMOX一線治療晚期膽道癌III期研究結果在2026年ASCO年會正式發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2638546521","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638546521?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 08:20","pubTimestamp":1779841243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份 发布公告，本公司创新免疫新药恩维达的一项III期关键性临床研究成果，成功在2026年美国临床肿瘤学会年会上正式发布。晚期胆管癌预后差、临床治疗手段有限，未满足临床需求巨大，本次III期研究数据的公开，将进一步验证本品在肝胆肿瘤领域的临床价值，进一步拓展中国市场销售适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01244","BK4134","BK1161","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638547290","title":"MediWound第一財季業績前瞻：EscharEx III期數據成關注焦點","url":"https://stock-news.laohu8.com/highlight/detail?id=2638547290","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638547290?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 03:44","pubTimestamp":1779824640,"startTime":"0","endTime":"0","summary":"以色列生物制药公司MediWound将于周三盘前发布2026年第一季度财报。市场将密切关注其商业化产品NexoBrid的销售进展，以及备受关注的EscharEx慢性伤口治疗药物III期临床试验的最新动态。 回顾3月5日发布的第四财季业绩，MediWound交出了一份喜忧参半的成绩单。 进入第一财季，华尔街对MediWound的预期较为保守。 除临床试验外，MediWound还有两项关键催化剂值得关注。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-27/doc-inhzhicw2494622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":176,"code":"91000000","status":"200"}]}}